IPA Joins Patient & Provider Organizations in Support of Bipartisan Bill to Protect Patient Access to Cancer and Complex Therapies

August 22, 2025

IPA joined 67 patient and provider organizations across the nation in applauding Congressmen Greg Murphy, Adam Gray, and Neal Dunn for introducing H.R. 4299, the Protecting Patient Access to Cancer and Complex Therapies Act of 2025.

This critical legislation protects patients and their providers from collateral damage in the Medicare drug price negotiation program between HHS and manufacturers. Historically, Part B drugs have been paid on an “Average Sales Price” (ASP)+6 percent methodology. The add-on payment is the key component of reimbursement for provider-administered drugs. Under the Inflation Reduction Act (IRA), however, negotiated Part B drugs will no longer be based on ASP but instead on a lower rate called the “Maximum Fair Price” (MFP). The Congressional Budget Office projects provider reimbursement reductions of 50 percent or more, including cuts to the add-on payment for providers administering Part B drugs. These reductions will have enormous negative ramifications for physicians and infusion facilities, limiting their ability to provide these medications to patients.

The Protecting Patient Access to Cancer and Complex Therapies Act would replace reimbursement reductions with an equivalent rebate paid by pharmaceutical manufacturers to CMS. This achieves the same amount of savings for the program while ensuring Medicare beneficiaries will benefit from lower negotiated rates and coinsurance. Importantly, the bill would maintain providers’ existing reimbursement, protect access to care in community-based settings, and prevent patients and providers from becoming collateral damage in negotiations. A new analysis estimates the legislation would generate $3.3 billion in savings over 10 years, because the sequester would apply to the ASP price instead of the lower Maximum Fair Price (MFP)+6 percent.

We look forward to working with Congress to advance this legislation to preserve high-quality care and protect patient access in community-based infusion settings.

To view the coalition letter, click here. IPA’s statement applauding introduction of the legislation can be viewed here.

About the Infusion Providers Alliance

The Infusion Providers Alliance (IPA) is committed to protecting the integrity of the provider-patient relationship by empowering providers and patients to choose the most appropriate treatment together. We advocate for policies that ensure timely and adequate patient access to high quality care in IPA members’ convenient, community-based, non-hospital settings. IPA members operate over 1,000 in-office or stand-alone ambulatory infusion centers across 43 states nationwide, delivering value to the health care system and improved outcomes to patients.

All inquiries should be emailed to ewarren@infusionprovidersalliance.org.